Carboplatin Shortage: What Providers and Prescribers Need to Know in 2026

Carboplatin has been on the FDA's active drug shortage list since April 2023 — over three years of sustained disruption to one of the most essential agents in oncology pharmacotherapy. For oncologists, pharmacists, and oncology care teams, managing this shortage requires a systematic approach to inventory management, patient prioritization, clinical rationing, and communication. This article compiles the most up-to-date guidance and practical frameworks for 2026.

Current Supply Landscape (April 2026)

Per the ASHP Drug Shortage Detail (updated April 28, 2026), the following status applies:

Fresenius Kabi: 10 mg/mL 60 mL vials on back order; estimated release early May 2026.

Pfizer: 5 mL, 15 mL, and 45 mL vials available in limited supply with weekly releases only.

Accord, BPI Labs, Eugia US: varying availability — check with your GPO and wholesaler daily during allocation periods.

ASHP guidance emphasizes: "No single agent can be substituted for carboplatin." Any therapeutic substitution requires individualized assessment by a hematology-oncology specialist. Providers should consult NCCN and ASCO guidelines for indication-specific recommendations.

ASCO Rationing and Prioritization Framework

ASCO's multidisciplinary Drug Shortages Advisory Group has published guidance on prioritizing patients when carboplatin is in limited supply. Key principles include:

Prioritize patients receiving carboplatin with curative intent or with evidence of significant survival benefit

Consider deferring carboplatin in platinum-resistant recurrent settings where alternative, equally effective options exist

Apply conservation strategies including: dose rounding down to nearest vial size, extending cycle intervals by 1–2 weeks when clinically acceptable, and minimizing multi-vial waste

Refer patients to NCI-designated cancer centers or academic medical centers if your institution cannot obtain sufficient supply for curative-intent patients

Clinical Alternatives by Tumor Type

The following summarizes ASCO and NCCN guidance on alternatives when carboplatin cannot be obtained:

Ovarian cancer (first-line): Cisplatin + paclitaxel may substitute when patient can tolerate. Cisplatin-based regimens carry higher nephrotoxicity risk; GFR monitoring is essential.

Recurrent platinum-resistant ovarian cancer: Non-platinum options (PLD, topotecan, gemcitabine, niraparib/olaparib in BRCA-mutant) are clinically appropriate and conserve platinum supply.

NSCLC: Cisplatin-doublets are acceptable substitutes in fit patients (ECOG 0–1, adequate renal function). For EGFR-mutant NSCLC, osimertinib-based regimens are NCCN Category 1. For high PD-L1 expressors, pembrolizumab monotherapy avoids platinum entirely.

SCLC (extensive-stage): Cisplatin + etoposide ± immunotherapy may substitute. Carboplatin + etoposide + atezolizumab + lurbinectedin maintenance is the NCCN-preferred regimen — preserve carboplatin allocation for these patients when possible.

Cervical cancer (chemoradiation): Cisplatin 40 mg/m² weekly remains preferred. Carboplatin AUC 2 IV weekly is the recommended alternative when cisplatin is not available. Reserve platinum for curative chemoradiation; consider omitting in intermediate-risk adjuvant settings.

Pharmacy and Operations Best Practices

Maintain real-time communication with your GPO account representative about weekly allocation and expected release dates.

Establish a formal clinical committee process for carboplatin allocation decisions, with ethics consultation available for difficult prioritization cases.

Consider vial-sharing protocols: one opened vial can serve multiple patients on the same treatment day if doses are scheduled concurrently, reducing waste.

Note FDA guidance: vial-size rounding (to the nearest commercially available vial size) is recommended to minimize waste without meaningful clinical impact for most dosing ranges.

Supporting Your Patients Through the Shortage

Patients will be anxious and need clear communication about any treatment changes. Be proactive in explaining the reason for delays or regimen modifications, and reassure patients that priority decisions are based on clinical evidence. To help your patients find carboplatin availability in their area, consider referring them to medfinder for providers, which calls pharmacies and infusion centers to locate drug availability on the patient's behalf.